Quick Answer
Verrica Pharmaceuticals Inc. reported Operating Income Loss of -$12.19 million for the year ending 2025.
- Verrica Pharmaceuticals Inc. showed an increase of +81.5% in Operating Income Loss from 2024 to 2025.
- This data is from Verrica Pharmaceuticals Inc.'s annual report (Form 10-K), filed with the SEC on March 11, 2026.
- XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2017: -$570.0 thousand | Q2 2017: -$1.10 million | Q3 2017: -$1.36 million | Q4 2017: -$1.43 million | Q1 2018: -$1.89 million | Q2 2018: -$5.47 million | Q3 2018: -$6.33 million | Q4 2018: -$8.19 million | Q1 2019: -$8.03 million | Q2 2019: -$7.52 million | Q3 2019: -$6.54 million | Q4 2019: -$7.99 million | Q1 2020: -$9.88 million | Q2 2020: -$8.63 million | Q3 2020: -$9.64 million | Q1 2021: $60.0 thousand | Q2 2021: -$10.73 million | Q3 2021: -$11.77 million | Q1 2022: -$7.41 million | Q2 2022: -$9.12 million | Q3 2022: $1.45 million | Q1 2023: -$7.09 million | Q2 2023: -$11.62 million | Q3 2023: -$23.92 million | Q1 2024: -$18.60 million | Q2 2024: -$15.21 million | Q3 2024: -$20.70 million | Q1 2025: -$8.13 million | Q2 2025: $1.51 million | Q3 2025: $1.63 million.
- Over the full 9 years of available data (2017 to 2025), Verrica Pharmaceuticals Inc.'s Operating Income Loss has declined by 173.4%.
- Historical annual values: Fiscal year 2025: -$12.19 million | Fiscal year 2024: -$65.92 million | Fiscal year 2023: -$65.76 million | Fiscal year 2022: -$21.30 million | Fiscal year 2021: -$30.91 million | Fiscal year 2020: -$40.18 million | Fiscal year 2019: -$30.08 million | Fiscal year 2018: -$21.88 million | Fiscal year 2017: -$4.46 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: